On Aug. 13, 2012, the Federal Trade Commission (FTC) announced proposed changes to the premerger notification rules that would require pharmaceutical companies to report proposed acquisitions of exclusive patent rights.  The proposed changes clarify when a transfer of exclusive rights to a patent in the pharmaceutical industry must be reported as an asset acquisition under the Hart-Scott-Rodino (HSR) Act.  Public comments on the proposed changes will be accepted until Oct. 25, 2012.